- Home
- KTB vs SLNO Comparison
KTB vs SLNO Comparison
Compare KTB & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTB
- SLNO
- Stock Information
- Founded
- KTB 2018
- SLNO 1999
- Country
- KTB United States
- SLNO United States
- Employees
- KTB N/A
- SLNO N/A
- Industry
- KTB Apparel
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- KTB Consumer Discretionary
- SLNO Health Care
- Exchange
- KTB Nasdaq
- SLNO Nasdaq
- Market Cap
- KTB 3.6B
- SLNO 3.2B
- IPO Year
- KTB N/A
- SLNO 2014
- Fundamental
- Price
- KTB $69.45
- SLNO $75.29
- Analyst Decision
- KTB Strong Buy
- SLNO Strong Buy
- Analyst Count
- KTB 5
- SLNO 9
- Target Price
- KTB $88.00
- SLNO $103.33
- AVG Volume (30 Days)
- KTB 746.1K
- SLNO 744.8K
- Earning Date
- KTB 05-06-2025
- SLNO 05-07-2025
- Dividend Yield
- KTB 3.03%
- SLNO N/A
- EPS Growth
- KTB 3.07
- SLNO N/A
- EPS
- KTB 4.07
- SLNO N/A
- Revenue
- KTB $2,599,277,000.00
- SLNO N/A
- Revenue This Year
- KTB $12.67
- SLNO N/A
- Revenue Next Year
- KTB $7.96
- SLNO N/A
- P/E Ratio
- KTB $16.85
- SLNO N/A
- Revenue Growth
- KTB 1.08
- SLNO N/A
- 52 Week Low
- KTB $50.00
- SLNO $36.93
- 52 Week High
- KTB $96.80
- SLNO $80.99
- Technical
- Relative Strength Index (RSI)
- KTB 51.38
- SLNO 50.25
- Support Level
- KTB $67.83
- SLNO $72.59
- Resistance Level
- KTB $71.08
- SLNO $78.32
- Average True Range (ATR)
- KTB 1.70
- SLNO 2.70
- MACD
- KTB -0.66
- SLNO -0.63
- Stochastic Oscillator
- KTB 12.16
- SLNO 32.52
About KTB Kontoor Brands Inc.
Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.